Back

Upscaling production of immunogenic poliovirus virus-like particles in Pichia Pastoris by controlled fermentation

Sherry, L.; Grehan, K.; Bahar, M. W.; Swanson, J. J.; Fox, H.; Matthews, S. V.; Carlyle, S.; Qin, L.; Porta, C.; Wilkinson, S.; Robb, S.; Clark, N.; Liddell, J.; Fry, E. E.; Stuart, D. I.; Macadam, A.; Rowlands, D. J.; Stonehouse, N. J.

2024-11-07 microbiology
10.1101/2024.11.07.622482 bioRxiv
Show abstract

The success of the poliovirus (PV) vaccines has enabled the near-eradication of wild PV, however, their continued use post-eradication poses a significant threat to maintaining a polio-free world. Recombinant virus-like particles (VLPs) that lack the viral genome remove this risk. Here, we demonstrate the production of PV VLPs for all three serotypes by controlled fermentation using Pichia pastoris. We determined the cryo-EM structure of a new PV-2 mutant, termed SC5a, in comparison to PV-2 SC6b VLPs described previously and investigated the immunogenicity of PV-2 SC5a VLPs. Finally, a trivalent immunogenicity trial using bioreactor-derived VLPs of all three serotypes in the presence of Alhydrogel adjuvant, showed that these VLPs outperform the current IPV vaccine in the standard vaccine potency assay, offering the potential for dose-sparing. Overall, these results provide further evidence that yeast-produced VLPs have the potential to be a next-generation polio vaccine in a post-eradication world.

Matching journals

The top 1 journal accounts for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.